Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
$1.10
-$0.12(-5.94%)
At close: 4:00 PM EST
$1.10
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.83 - $3.48
Previous Close$1.96
Volume269.01K
Average Volume (3M)5.25M
Market Cap
$148.06M
Enterprise Value$118.88M
Total Cash (Recent Filing)$22.29M
Total Debt (Recent Filing)$61.72M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Nov 12, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding132,193,770
10 Day Avg. Volume2,932,318
30 Day Avg. Volume5,247,998
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.16
Price to Sales (P/S)964.47
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue6.99K
Enterprise Value/Gross Profit-216.14
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$6.52Price Target Upside492.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInitial preclinical data from RJVA-002 validate its feasibility and signal weight loss efficacy.
Financial OutlookA recent offering completed in August raised approximately $23M, with additional potential proceeds from warrants, extending cash runway into 2026.
Safety ProfileNo adverse events were reported in Rejuva-treated animals, indicating a favorable safety profile.
Bears Say
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.82 and its highest was $3.48 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $148.06M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 4 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.564 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.204.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 132,193,770 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.564 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went up 3.061%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.52 (492.73% Upside)
$6.52 (492.73% Upside)
Hedge Fund Trend
Decreased
By 21.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.19%
12-Months-Change
Fundamentals
Return on Equity
-379.75%
Trailing 12-Months
Asset Growth
-57.66%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc. (GUTS) is a biotechnology company focused on transforming the treatment landscape for metabolic diseases, particularly type 2 diabetes and obesity. The company operates in the healthcare sector and is recognized for its innovative approach to metabolic health, leveraging advanced technologies to develop therapies that target the underlying causes of these conditions. Fractyl's core product is the Revita procedure, a minimally invasive endoscopic technique designed to improve metabolic function and promote weight loss through the modulation of gut hormones.
GUTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Fractyl Health's earnings call highlighted several positive developments, including a strengthened financial position, strategic focus on reducing cash burn, and promising data from the Revita program. However, the company also reported an increased net loss and highlighted dependence on future data readouts for continued success. The overall sentiment is cautiously optimistic, with significant potential contingent on upcoming results.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$6.52
▲(492.73% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Genfit SA
―
Innate Pharma
―
Ownership Overview
16.37% Insiders
1.60% Mutual Funds
17.43% Other Institutional Investors
63.39% Public Companies and Individual Investors
Options Prices
Currently, No data available
---